A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.

MLA

Juergens, Rosalyn A., et al. “A Phase IB Study of Durvalumab with or without Tremelimumab and Platinum-Doublet Chemotherapy in Advanced Solid Tumours: Canadian Cancer Trials Group Study IND226.” Lung Cancer (Amsterdam, Netherlands), vol. 143, May 2020, pp. 1–11. EBSCOhost, https://doi.org/10.1016/j.lungcan.2020.02.016.

APA

Juergens, R. A., Hao, D., Ellis, P. M., Tu, D., Mates, M., Kollmannsberger, C., Bradbury, P. A., Tehfe, M., Wheatley-Price, P., Robinson, A., Bebb, G., Laskin, J., Goffin, J., Hilton, J., Tomiak, A., Hotte, S., Goss, G. D., Brown-Walker, P., Sun, X., … Laurie, S. A. (2020). A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer (Amsterdam, Netherlands), 143, 1–11. https://doi.org/10.1016/j.lungcan.2020.02.016

Chicago

Juergens, Rosalyn A, Desiree Hao, Peter M Ellis, Dongsheng Tu, Mihaela Mates, Christian Kollmannsberger, Penelope A Bradbury, et al. 2020. “A Phase IB Study of Durvalumab with or without Tremelimumab and Platinum-Doublet Chemotherapy in Advanced Solid Tumours: Canadian Cancer Trials Group Study IND226.” Lung Cancer (Amsterdam, Netherlands) 143 (May): 1–11. doi:10.1016/j.lungcan.2020.02.016.